Back to Search Start Over

Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia.

Authors :
Kim SW
Kim KM
Kim JM
Shin IS
Shin HY
Yang SJ
Yoon JS
Source :
Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2007 Mar 30; Vol. 31 (2), pp. 543-5. Date of Electronic Publication: 2006 Nov 15.
Publication Year :
2007

Abstract

Data on the use of long-acting injectable (LAI) risperidone, the first atypical depot antipsychotic, during pregnancy are limited. A 35-year-old woman with schizophrenia was given LAI risperidone before and throughout her pregnancy. She gave birth to a female infant weighing 2230 g at 36 weeks and 6 days of pregnancy, following premature rupture of the membranes. The baby had no congenital malformation and was healthy 8 months postnatal. To our knowledge, this is the first reported use of LAI risperidone throughout an entire pregnancy. In this paper, we discuss the rationale and problems of LAI risperidone use in pregnancy, based on a literature review.

Details

Language :
English
ISSN :
0278-5846
Volume :
31
Issue :
2
Database :
MEDLINE
Journal :
Progress in neuro-psychopharmacology & biological psychiatry
Publication Type :
Academic Journal
Accession number :
17110011
Full Text :
https://doi.org/10.1016/j.pnpbp.2006.09.017